Glycemic Variability, Gut Microbiota, and Prognosis in T2DM With ACS

Launched by SECOND AFFILIATED HOSPITAL OF NANCHANG UNIVERSITY · Aug 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how changes in blood sugar levels (glycemic variability), the bacteria in our gut (gut microbiota), and their effects on health relate to patients who have type 2 diabetes and have recently experienced a heart issue known as acute coronary syndrome (ACS). Researchers are monitoring blood sugar levels using a special device for up to 14 days while also collecting stool and blood samples to better understand the connection between these factors and the heart health of patients over time.

To participate in this study, individuals should be diagnosed with both type 2 diabetes and acute coronary syndrome. However, certain conditions such as recent antibiotic use, pregnancy, or severe skin problems may prevent someone from joining. Participants can expect to wear a continuous glucose monitor and provide samples during their hospital stay, with follow-up assessments for at least a year to track any heart-related health issues. This trial aims to provide valuable insights that could improve care for patients with these conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Type 2 Diabetes Mellitus (T2DM).
• • Clinical diagnosis of Acute Coronary Syndrome (ACS).
• Exclusion Criteria:
• • History of hemodialysis.
• • Recent antibiotic use within the past two weeks.
• • Active malignant tumors.
• • Pregnancy and breastfeeding.
• • Inability to wear sensors due to severe skin conditions.
• • Coagulation disorders, anemia, or abnormal hematocrit levels.
• • Requirement for MRI during the sensor-wearing period.
• • Inability to follow study instructions or deemed unsuitable for the trial by the treating clinician/nurse.
• • Inability to understand informed consent or communicate with researchers due to cognitive decline or mental illness.